Arjune Sen, Mary Akinola, Xin You Tai, Mkael Symmonds, Gabriel Davis Jones, Sergio Mura, Joanne Galloway, Angela Hallam, Jane Y C Chan, Ivan Koychev, Chris Butler, John Geddes, Rohan Van Der Putt, Sian Thompson, Sanjay G Manohar, Eleni Frangou, Sharon Love, Rupert McShane, Masud Husain
BACKGROUND: Although Alzheimer's disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer's disease than age matched controls, may contribute to the loss of nerve cells and abnormal brain discharges can disrupt cognition. This aberrant electrical activity may therefore present potentially important drug targets. The anti-seizure medication levetiracetam can reduce abnormal cortical discharges and reverse memory deficits in a mouse model of Alzheimer's disease...
July 31, 2021: Trials